TILT Biotherapeutics

TILT Biotherapeutics is a Finnish-American biotech pioneering oncolytic immunotherapies to treat solid tumors. Its core TILT® technology platform utilizes engineered adenoviruses armed with immunostimulatory cytokines, delivered intravenously, to turn 'cold' tumors 'hot' and enhance T-cell therapies. The lead asset, TILT-123, is in Phase I trials in the US and Europe, both as a monotherapy and in combination with checkpoint inhibitors or TIL therapy. The company operates as a private, pre-revenue entity with a team of approximately 20, pursuing a therapeutics business model through internal development and strategic partnerships.

Patented TILT® technology platform using engineered, cytokine-armed oncolytic adenoviruses delivered intravenously. The viruses are designed to selectively infect and lyse cancer cells while delivering immunostimulatory cytokines (e.g., TNF, IL-2) directly to the tumor microenvironment to stimulate T-cell responses and turn 'cold' tumors 'hot'.

Tiltbio operates in the competitive oncolytic virotherapy and immuno-oncology enabling space. Direct competitors include companies like Oncolytics Biotech, DNAtrix, and Turnstone Biologics. It also competes indirectly with all firms developing T-cell engagers, cytokine therapies, and tumor microenvironment modulators. Its key differentiators are the specific TNF/IL-2 cytokine combination and the focus on intravenous delivery for systemic reach.